NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NEI E-192-2014-1-EP-10 Surgical Tool and Method for Ocular Tissue Transplantation EP DIV 23215832.9 Pending
NCI E-233-2014-0-AU-01 METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION AU DIV 2023282185 Pending
NCATS E-116-2016-0-JP-01 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE JP DIV 2023-208374 Pending
NHGRI E-044-2013-1-SG-01 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SG DIV 10202303471P Pending
NIA E-249-2016-0-SG-01 METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM AND METHODS OF TREATING A CENTRAL NERVOUS SYSTEM DISEASE SG DIV 10202303473R Pending
NCI E-118-2021-0-CN-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors CN National Stage 2022800415318 Pending
NCI E-106-2021-0-CA-01 COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME CA National Stage 3222837 Pending
NCI E-106-2021-0-JP-01 COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME JP National Stage 2023-575827 Pending
NHLBI E-127-2021-2-EP-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES EP National Stage 22726911.5 Pending
NCI E-106-2021-0-US-02 COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME US National Stage 18/568,738 Pending
NCI E-148-2021-0-US-02 COMPOSITIONS AND METHODS FOR DETERMINING RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITORS (ICI), INCREASING EFFECTIVENESS OF ICI, AND TREATING CANCER US National Stage 18/568,661 Pending
NCI E-118-2021-0-US-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors US National Stage 18/567,990 Pending
NIAID E-051-2023-0-PC-01 HYDROGEL PURIFICATION OF CELL MATERIALS FOR PCR-ACTIVATED CELL SORTING PCT PCT PCT/US2023/082816 Pending
NIDDK E-033-2023-0-PC-01 Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity PCT PCT PCT/US2023/082871 Pending
NIAID E-150-2021-0-PC-01 NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST WESTERN, EASTERN, AND VENEZUELAN EQUINE ENCEPHALITIS VIRUS (EVV) PCT PCT PCT/US2023/082822 Pending
NCI E-082-2023-0-PC-01 LIGANDS SPECIFIC FOR ASCT1 PCT PCT PCT/EP2023/084599 Pending
NCATS E-091-2016-0-IN-01 COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE IN DIV 202318083229 Pending
NCI E-101-2021-0-AU-04 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 AU National Stage 2022268998 Pending
NCI E-099-2014-0-JP-02 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF JP DIV 2023-205633 Pending
NIDA E-053-2023-0-PCT-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PCT PCT PCT/US2023/082355 Pending
NCI E-142-2022-0-PC-01 Topoisomerase Ill (TOP3) inhibitors and antiviral compounds based on bisacridines PCT PCT PCT/US2023/082186 Pending
NCI E-101-2021-0-KR-06 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 KR National Stage 2023-7041691 Pending
NIAID E-028-2024-0-PC-01 Peptides And Peptide Micro Arrays For Detection And Differentiation Of Antibody Responses To Ebola Virus And Other Pathogens PCT PCT PCT/US2023/081625 Pending
NIAID E-131-2020-8-US-01 Anti-Coronavirus Antibodies And Methods Of Use US DIV 18/524,940 Pending
NCI E-183-2017-0-US-02 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS US CON 18/524,799 Pending
NHGRI E-044-2013-1-AU-01 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA AU DIV 2023274161 Pending
NIAAA E-087-2021-0-EP-01 A FACILE AND ODOR-FREE APPROACH TO CONVERT UREA/SULFONYL UREA TO CHALCOGENIDE UREA/ SULFONYL UREA EP National Stage 22729881.7 Pending
NCI E-173-2020-0-HK-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 HK EP 62023083439.7 Pending
NCI E-027-2022-0-PC-01 TOPOISOMERASE Ill (TOP3) INHIBITORS AND ANTIVIRAL COMPOUNDS BASED ON CYANINES PCT PCT PCT/US2023/081638 Pending
NEI E-153-2020-0-CA-04 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells CA National Stage 3220433 Pending
NCI E-046-2019-1-US-01 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS US CON 18/520,027 Pending
NEI E-155-2020-0-JP-06 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS JP National Stage 2023-572794 Pending
NEI E-153-2020-0-JP-05 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS JP National Stage 2023-572792 Pending
NCI E-171-2018-7-EP-01 MODIFIED CELLS AND METHODS OF THERAPY EP DIV 23211577.4 Pending
NCI E-101-2021-0-EP-08 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 EP National Stage 22726335.7 Pending
NCI E-174-2018-2-EP-01 TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY EP DIV 23211578.2 Pending
NIDDK E-112-2021-0-US-02 Vitamin C Renal Leak As A Clinical Diagnostic Tool In The Detection, Monitoring And Management Of Acute And Chronic Diseases US National Stage 18/563,663 Pending
NHLBI E-127-2021-2-CN-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES CN National Stage 202280037094.2 Pending
NICHD E-028-2020-0-US-02 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING US National Stage 18/563,237 Pending
NCI E-191-2019-0-EP-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION EP National Stage 22721599.3 Pending
NEI E-155-2020-0-US-02 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS US National Stage 18/562,806 Pending
NEI E-155-2020-0-CA-05 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS CA National Stage 3220602 Pending
NCI E-239-2017-0-NZ-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS NZ DIV 805541 Pending
NIAAA E-087-2021-0-US-02 A FACILE AND ODOR-FREE APPROACH TO CONVERT UREA/SULFONYL UREA TO CHALCOGENIDE UREA/ SULFONYL UREA US National Stage 18/561,068 Pending
NCI E-027-2023-0-PC-01 REAL-TIME REMOTE CONTROLLED MICROSCOPY AND COMMUNICATIONS OVER A NETWORK PCT PCT PCT/US2023/079836 Pending
NCI E-065-2021-0-CN-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF CN National Stage 202280034971.0 Pending
NCATS E-039-2021-0-JP-01 METHODS AND SYSTEMS FOR SOLID PHASE EXTRACTION JP National Stage 2023-557052 Pending
NINDS E-018-2024-0-PCT-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA PCT PCT PCT/US2023/079547 Pending
NEI E-153-2020-0-US-02 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells US National Stage 18/290,396 Pending
NCI E-264-2011-0-US-02 DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS US CON 18/507,690 Pending